Online inquiry

IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4601MR)

This product GTTS-WQ4601MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014218.3; NM_014219.2; NM_015868.3; NM_014512.1; KIR2DS2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3802; 3803; 3804; 3806; 100132285
UniProt ID P43626; P43627; P43628; Q14954; P43631
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4601MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12917MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ5934MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ5472MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ3043MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ1999MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ10721MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ554MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ5752MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW